DDInter1928 DDInter1376
Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Verapamil {u} (Compound) resembles {v} (Compound) Bevantolol
Verapamil {u} (Compound) resembles {v} (Compound) Trimethobenzamide
Verapamil {u} (Compound) treats {v} (Disease) migraine
Verapamil {u} (Compound) binds {v} (Gene) CACNB2
Verapamil {u} (Compound) upregulates {v} (Gene) MCOLN1
Verapamil {u} (Compound) is included by {v} (Pharmacologic Class) Calcium Channel Antagonists
Verapamil {u} (Compound) downregulates {v} (Gene) DNAJA3
Verapamil {u} (Compound) causes {v} (Side Effect) Diarrhoea
Verapamil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Verapamil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Verapamil (Compound) resembles Bevantolol (Compound)
Verapamil (Compound) resembles Trimethobenzamide (Compound)
Verapamil (Compound) treats migraine (Disease)
Verapamil (Compound) binds CACNB2 (Gene)
Verapamil (Compound) upregulates MCOLN1 (Gene)
Verapamil (Compound) is included by Calcium Channel Antagonists (Pharmacologic Class)
Verapamil (Compound) downregulates DNAJA3 (Gene)
Verapamil (Compound) causes Diarrhoea (Side Effect)
Verapamil may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Verapamil may cause a minor interaction that can limit clinical effects when taken with Bexarotene